No 2: Vol 6, Supplement 2 (March 2017): Translational Cancer Research

Editorial

Osimertinib for pretreated epidermal growth factor receptor Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study

Mie Kotake, Tateaki Naito, Akira Ono, Hirotsugu Kenmotsu, Haruyasu Murakami, Toshiaki Takahashi

PDF Pages: S235-S238 Full Text Open Access

Molecular resistance mechanisms of ALK inhibitors and implications for therapeutic management of ALK-rearranged lung cancer patients

Xiaomin Niu, Sandra Perdomo, Fiona Blackhall

PDF Pages: S239-S245 Full Text Open Access

Localized prostate cancer genotyping: another step towards personalized therapy

Chiara Ciccarese, Rodolfo Montironi, Roberto Iacovelli, Francesco Massari

PDF Pages: S246-S248 Full Text Open Access

Poor survival with high-dose chemotherapy and autologous stem cell support in double-hit and double-expressor B-cell lymphomas

Patrick M. Reagan, Jonathan W. Friedberg

PDF Pages: S249-S253 Full Text Open Access

Facing pseudoprogression after radiotherapy in low grade gliomas

Fernando Carceller, Henry Mandeville, Andrew D. Mackinnon, Frank Saran

PDF Pages: S254-S258 Full Text Open Access

Can we efficiently and safely combine a pan-class I phosphatidylinositol-3-kinase inhibitor with paclitaxel in metastatic breast cancer?

Jacques Raphael, John M. Bartlett, Kathleen I. Pritchard

PDF Pages: S259-S264 Full Text Open Access

Osimertinib in advanced EGFR T790M-positive non-small-cell lung cancer: the clinical impact of AURA3

Robert Pirker, Anna Buder, Martin Filipits

PDF Pages: S265-S269 Full Text Open Access

Are all ALK rearrangements created equal?

Michael Duruisseaux, Anne Mc Leer-Florin, Denis Moro-Sibilot, Jacques Cadranel

PDF Pages: S270-S275 Full Text Open Access

Low-frequency ultrasound may improve drug penetration in colonic mucosa

Qiubing Chen, Bo Xiao, Didier Merlin

PDF Pages: S276-S279 Full Text Open Access

IL-6, cancer and cachexia: metabolic dysfunction creates the perfect storm

James P. White

PDF Pages: S280-S285 Full Text Open Access

Relevance of the Hedgehog pathway in T-cell acute lymphoblastic leukemia

Jasmin Wellbrock, Walter Fiedler

PDF Pages: S286-S291 Full Text Open Access

A story of ALK variants and the efficacy of ALK inhibitors: moving toward precision oncology

Hai-Yan Tu, Yi-Chen Zhang, Yi-Long Wu

PDF Pages: S292-S295 Full Text Open Access

NLRC3 mediated PI3K-mTOR inhibition takes a toll on colon cancer

Nidhi Sharma, Sushmita Jha

PDF Pages: S296-S300 Full Text Open Access

Lessons from the NOVA trial: an editorial on results, biomarkers, and patient selection for PARP inhibition in recurrent ovarian cancer

Kathryn P. Pennington, Barbara M. Norquist, Elizabeth M. Swisher

PDF Pages: S301-S305 Full Text Open Access

Immunotherapy’s new challenge: identification of predictive biomarkers for tumor response

Charlotte Domblides, Anne-Marie Ruppert, Martine Antoine, Marie Wislez

PDF Pages: S306-S308 Full Text Open Access

Exploring gold nanoparticle interactions with proteins and the tumor microenvironment in biological systems

Li Tian, Ashley Chang, Marites P. Melancon

PDF Pages: S309-S312 Full Text Open Access

Postoperative seizure control in glioma patients with epilepsy

Johan A. F. Koekkoek, Charles J. Vecht

PDF Pages: S313-S316 Full Text Open Access

Normalizing tumoral vessels to treat cancer: an out-of-the-box strategy involving TIE2 pathway

Juan Fueyo, Mohammad B. Hossain, Teresa Nguyen, Candelaria Gomez-Manzano

PDF Pages: S317-S320 Full Text Open Access

Rogue one: another faction of the Wnt empire implicated in assisting GBM progression

Riasat Ahsan, Shivani Baisiwala, Atique U. Ahmed

PDF Pages: S321-S327 Full Text Open Access

The emerging role of Interleukin-21 as an antineoplastic immunomodulatory treatment option

George Zarkavelis, Aristeidis Kefas, George Pentheroudakis

PDF Pages: S328-S330 Full Text Open Access

Current and emerging perspectives on immunotherapy for pancreatic cancer

Inamul Haque, Arvind Subramanian, Snigdha Banerjee, Sushanta K. Banerjee

PDF Pages: S331-S336 Full Text Open Access

Glioma-associated epilepsy: toward mechanism-based treatment

Tom J. Snijders, Sharon Berendsen, Tatjana Seute, Pierre A. Robe

PDF Pages: S337-S341 Full Text Open Access

Transient receptor potential, Melastatin-2 (TRPM2) blockade: perspectives on potential novel clinical utility in cancer

Steven D. Blake, Christopher M. Tweed, Shelby G. McKamey, David W. Koh

PDF Pages: S342-S347 Full Text Open Access

Development of predictive liquid biomarkers for response to treatment in small cell lung cancer

Nahomi Tokudome, Nobuyuki Yamamoto

PDF Pages: S348-S352 Full Text Open Access

Circulating tumor cells as a liquid biopsy in small cell lung cancer, a future editorial

Menno Tamminga, Harry J. M. Groen, T. Jeroen. N. Hiltermann

PDF Pages: S353-S356 Full Text Open Access

Uncertainties of cumulative dose assessment for prostate IMRT

Jung-in Kim, Jin Ho Kim, Jong Min Park

PDF Pages: S357-S359 Full Text Open Access

Adjuvant therapy in renal-cell carcinoma: Is it prime time yet?

John Dimitriadis, Aristotelis Bamias

PDF Pages: S360-S362 Full Text Open Access

TOURMALINE-MM1: new oral triplet combination for patients with relapsed/refractory multiple myeloma

Esraa Abu-Rashed, Joseph Sharif, Alberto Rocci

PDF Pages: S363-S365 Full Text Open Access

KDM1 links nuclear GSK3β to epigenetic alterations

Weijie Guo, Binhua P. Zhou

PDF Pages: S366-S368 Full Text Open Access

Dividing and conquering the variation among variants in EML4-ALK lung cancer

Trever G. Bivona

PDF Pages: S369-S370 Full Text Open Access

Will PI3K-targeted therapies for cancer become a reality?

Maitri Kalra, Harikrishna Nakshatri

PDF Pages: S371-S375 Full Text Open Access

Editorial to “Palbociclib and letrozole in advanced breast cancer”

Joanne W. Chiu, Gerry Kwok, Thomas Yau, Roland Leung

PDF Pages: S376-S379 Full Text Open Access

Brigatinib and the new generation of ALK-inhibitors for non-small cell lung cancer

Neal S. McCall, Bo Lu

PDF Pages: S380-S383 Full Text Open Access

Unlocking the epigenetic code of T cell exhaustion

Jiazhu Wu, Huidong Shi

PDF Pages: S384-S387 Full Text Open Access

The CXCL12/CXCR4 pathway or the autocrine proliferative loop of the glioblastoma stem cells

Bernard Rogister

PDF Pages: S388-S390 Full Text Open Access

Genomic mutational profiles of metastatic breast cancer: obtaining them early and during the continuum of oncological care

Victor C. Kok

PDF Pages: S391-S394 Full Text Open Access

TRPV1: a channel for mammalian sperm thermotaxis?

Serafín Pérez-Cerezales, Pablo Bermejo-Álvarez

PDF Pages: S395-S398 Full Text Open Access

New insights into human testicular germ cell tumors: miR-223-3p gains oncogene function

Erika Di Zazzo, Bruno Moncharmont

PDF Pages: S399-S401 Full Text Open Access

Quantification of PD-L1 expression in non-small cell lung cancer

Vivek Verma, Joe Y. Chang

PDF Pages: S402-S404 Full Text Open Access

Translating prognostic prostate cancer gene signatures into the clinic

Ananya Choudhury, Catharine M. L. West

PDF Pages: S405-S408 Full Text Open Access

Subcellular localization of TRPM2 determines the fate of cancer cells, apoptosis or survival

Makiko Kashio, Makoto Tominaga

PDF Pages: S409-S411 Full Text Open Access

Avoiding both the surgically and oncologically futile use of ALPPS

Yasuyuki Fukami

PDF Pages: S412-S413 Full Text Open Access

The subtype-specific role of histone H1.0 in cancer cell differentiation and intratumor heterogeneity

Alicia Roque, Inma Ponte, Pedro Suau

PDF Pages: S414-S417 Full Text Open Access

Genome-based modeling for adjusting radiotherapy dose (GARD)-a significant step toward the future of personalized radiation therapy

Michael J. Baine, Chi Lin

PDF Pages: S418-S420 Full Text Open Access

Bevacizumab in small cell lung cancer

Giandomenico Roviello, Daniele Generali

PDF Pages: S421-S423 Full Text Open Access

When is KRAS or TP53 mutation predictive of response to immunotherapy for lung cancer?

Tawee Tanvetyanon

PDF Pages: S424-S426 Full Text Open Access

Mechanisms of the sperm guidance, an essential aid for meeting the oocyte

Raquel Lottero-Leconte, Carlos Agustín Isidro Alonso, Luciana Castellano, Silvina Perez Martinez

PDF Pages: S427-S430 Full Text Open Access

Hepatopancreaticoduodenectomy for biliary cancer: operative strategies determine near-zero operative mortality, but tumor biology determines an acceptable long-term outcome

Chun-Yi Tsai, Chun-Nan Yeh

PDF Pages: S431-S433 Full Text Open Access

CXCL12/CXCR4 signaling in glioma stem cells—prospects for therapeutic intervention

Tsubasa Miyazaki, Yoji Uemae, Eiichi Ishikawa

PDF Pages: S434-S437 Full Text Open Access

Letter to the Editor

Hidden in plain sight: promising therapeutic targets for glioblastoma lurk within DNA damage response pathways

Ross Carruthers, Anthony J. Chalmers

PDF Pages: S438-S440 Full Text Open Access

Synthetic lethality vs. synthetic viability due to PARP1 and BRCA2 loss

Xia Ding, Shyam K. Sharan

PDF Pages: S441-S442 Full Text Open Access

Differential microRNA expression in epithelial cell populations from human prostate: its relevance to treatment resistance in prostate cancer

Norman J. Maitland

PDF Pages: S443-S445 Full Text Open Access

How do the QUARTZ trial results inform future research for patients with brain metastases from non-small cell lung cancer?

Matthew Nankivell, Ruth E. Langley, Rachael Barton, Corinne Faivre-Finn, Paula Wilson, Elaine McColl, Barbara Moore, Iona Brisbane, David Ardron, Benjamin Sydes, Richard Stephens, Mahesh Parmar, Paula Mulvenna

PDF Pages: S446-S447 Full Text Open Access

Treatment approach for large-cell neuroendocrine carcinoma of the lung using next-generation sequencing

Shigeki Umemura, Tomohiro Miyoshi, Genichiro Ishii, Katsuya Tsuchihara

PDF Pages: S448-S449 Full Text Open Access

Transoral endoscopic thyroidectomy—essentiality of classification

Angkoon Anuwong

PDF Pages: S450-S452 Full Text Open Access

Disclosure:

This supplement was published without any sponsorship or funding.